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OBJECTIVES: The aim of this study was to examine the expression of the N-myc downstream-regulated gene 1
protein in benign and malignant lesions of the thyroid gland by immunohistochemistry.
INTRODUCTION: N-myc downstream-regulated gene 1 encodes a protein whose expression is induced by various
stimuli, including cell differentiation, exposure to heavy metals, hypoxia, and DNA damage. Increased N-myc
downstream-regulated gene 1 expression has been detected in various types of tumors, but the role of N-myc
downstream-regulated gene 1 expression in thyroid lesions remains to be determined.
METHODS: A tissue microarray paraffin block containing 265 tissue fragments corresponding to normal thyroid,
nodular goiter, follicular adenoma, papillary thyroid carcinoma (classical pattern and follicular variant), follicular
carcinoma, and metastases of papillary and follicular thyroid carcinomas were analyzed by immunohistochemistry
using a polyclonal anti- N-myc downstream-regulated gene 1 antibody.
RESULTS: The immunohistochemical expression of N-myc downstream-regulated gene 1 was higher in carcinomas
compared to normal thyroid glands and nodular goiters, with higher expression in classical papillary thyroid
carcinomas and metastases of thyroid carcinomas (P , 0.001). A combined analysis showed higher immunohisto-
chemical expression of NDRG1 in malignant lesions (classical pattern and follicular variant of papillary thyroid
carcinomas, follicular carcinomas, and metastases of thyroid carcinomas) compared to benign thyroid lesions (goiter
and follicular adenomas) (P = 0.043). In thyroid carcinomas, N-myc downstream-regulated gene 1 expression was
significantly correlated with a more advanced TNM stage (P = 0.007) and age, metastasis, tumor extent, and size
(AMES) high-risk group (P = 0.012).
CONCLUSIONS: Thyroid carcinomas showed increased immunohistochemical N-myc downstream-regulated gene 1
expression compared to normal and benign thyroid lesions and is correlated with more advanced tumor stages.
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INTRODUCTION
Thyroid cancer is the most common malignant tumor of
the endocrine system; approximately 37,200 new cases were
expected to occur in the United States in 2009.
1 In the city of
Sa ˜o Paulo, Brazil, 1207 and 6004 cases of thyroid cancer in
males and females, respectively, were identified from 1997
to 2003.
2 According to some studies, the increase in the
incidence of thyroid cancer can be explained by a higher
frequency of early tumor detection due to the use of more
sophisticated diagnostic techniques.
3,4 Thyroid carcinomas
that are derived from follicular epithelium can be classified
into well-differentiated carcinomas (including papillary and
follicular carcinomas), poorly differentiated carcinomas and
undifferentiated (or anaplastic) carcinomas, based on well-
established clinical findings and histological criteria.
5
However, despite standardized criteria and nomenclature,
variations exist in the histological classification of thyroid
tumors among different observers. This disagreement is
greater for encapsulated follicular thyroid tumors (ade-
noma, follicular carcinoma and some cases of the follicular
variant of papillary carcinoma), in which the histological
diagnosis is prone to subjective and discordant interpreta-
tions among pathologists.
6-8 Histological findings may not
be sufficient to establish a precise diagnosis and, conse-
quently, to predict the clinical courses of these cases.
Copyright  2010 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
CLINICS 2010;65(8):757-762 DOI:10.1590/S1807-59322010000800004
757Objective criteria and the identification of markers that
permit better characterization of thyroid tumors are there-
fore required.
9
N-myc downstream-regulated gene 1 (NDRG1) is a
member of the NDRG gene family and encodes a 43-kD
protein (NDRG1) with 394 amino acids.
10 NDRG1 is located
on human chromosome 8q24 and has been recognized as a
gene whose mutation is associated with a demyelinating
neuropathy called Charcot-Marie-Tooth disease, type 4D.
11
NDRG1 is ubiquitously expressed in human tissues, and its
messenger RNA has been detected in a variety of tissues,
such as the digestive and respiratory tracts, liver, pancreas,
kidneys, reproductive organs, placenta, skeletal muscle,
heart, and brain.
10,12 Immunohistochemical studies have
shown that the NDRG1 protein is mainly expressed in the
epithelial cells of different tissues, whereas no expression
could be demonstrated in mesenchymal or endothelial
cells.
12 Other members of the NDRG family (NDRG2,
NDRG3 and NDRG4) are homologous to the NDRG1 gene.
However, in contrast to NDRG1, these genes most likely
exert tissue-specific functions, as they are only expressed in
certain types of tissues.
13
NDRG1 protein expression is known to be induced by a
variety of physiological and pathological stimuli.
Expression of this protein is associated with cell growth
arrest and terminal cell differentiation, as observed in
squamous epithelial cells of the more superficial layers of
the epidermis.
12 During embryogenesis, NDRG1 expression
is repressed by N-Myc and c-Myc during cell proliferation
phases.
14 Conversely, ligands such as vitamin D and retinoic
acid, which bind to transcription factors involved in cell
differentiation, inhibit growth and induce cell differentia-
tion and NDRG1 expression.
15 Other factors, such as an
increase in intracellular calcium concentration, a reduction
in glucose concentration, hypoxia, DNA damage and
neoplasms, are also associated with NDRG1 expression.
16
Heavy metals (such as nickel) induce cellular hypoxia and
the expression of various genes that are responsive to
hypoxia, including NDRG1.
17,18
NDRG1 has also been characterized as a mediator of p53-
dependent, anti-oncogenic functions. Stein et al. demon-
strated that the p53-induced NDRG1 expression reduces cell
proliferation in metastatic pulmonary cancer cells.
19
However, the role of NDRG1 in tumor progression and the
formation of metastases is controversial. Some studies have
suggested that NDRG1 overexpression reduces the metastatic
potentialoftumorcells,
20,21whereasothershaveassociatedits
increased expression with less differentiated or more meta-
static aggressive tumors and a poor prognosis.
22,23
In the present study, we analyzed the quantitative
immunohistochemical expression of the NDRG1 protein in
normal thyroid glands and benign and malignant thyroid
lesions. We also investigated the correlation between
NDRG1 protein expression and clinical-pathological vari-
ables in cases of primary thyroid carcinoma. To our
knowledge, this is the first study to analyze NDRG1 protein
expression in benign and malignant thyroid lesions.
MATERIALS AND METHODS
Samples
Paraffin blocks from 225 patients, including 62 cases of
nodular goiter (NG), 53 cases of follicular adenoma (FA), 41
cases of classical papillary thyroid carcinoma (PTC), 31
cases of the follicular variant of papillary thyroid carcinoma
(FV-PTC), and 36 cases of follicular carcinoma (FC) were
selected from the archives of the Department of Pathology,
University of Sa ˜o Paulo Medical School (comprising the
period from 2000 to 2006) and the Department of Pathology,
A. C. Camargo Hospital (comprising the period from 1984
to 2001). Histological diagnoses were made according to the
classification of thyroid tumors proposed by the WHO.
5
When available, paraffin blocks of lymph node metastases
from thyroid carcinomas (M-TC) were also selected and
included 17 cases of metastatic PTC, 5 cases of metastatic
FV-PTC, and 1 case of metastatic FC. One case of bone
metastasis from FC was also included in the study. The
patient age ranged from 15 to 88 years (mean: 48.4 years
old), and 184 (81.8%) patients were female.
Data regarding the TNM stage
24 and age, metastasis, and
extent and size (AMES) death risk criteria
25 were obtained
from the clinical records of patients with thyroid carcinoma
(PTC, FV-PTC and FC). The median time of clinical follow-
up and the interval for recurrence for patients with thyroid
carcinoma was 53.5 months (range: 1 to 175 months) and
18.0 months (range: 2 to 48 months), respectively. No
clinical follow-up data were available for eight patients (six
with FC, one with PTC and one with FV-PTC). During this
period, 16 cases of recurrence (4 followed by death) and 4
cases of death due to disseminated metastatic disease were
observed. All deaths occurred in the group of patients with
FC, and four patients were alive but still had diseases (two
with PTC and two with FC).
This study was approved by the Ethics Committee for the
Analysis of Research Projects of the University of Sa ˜o Paulo
Medical School and the Research Ethics Committee of A. C.
Camargo Hospital.
Construction of the tissue microarray
Slides were prepared for the tissue microarray (TMA)
from the selected blocks, stained with hematoxylin-eosin
and examined under a binocular light microscope (Nikon,
Eclipse E100) for the selection of representative areas of the
lesion. The areas of interest in the slides were stained with
Indian ink and compared to the corresponding areas in the
paraffin blocks, which were also stained with Indian ink.
Using a tissue microarrayer (Beecher Instruments, Silver
Springs, MD, USA), the areas of interest in each block were
punctured with a 1-mm diameter needle, and cylindrical
fragments were transferred in an ordered fashion to a
recipient paraffin block (TMA block), as described pre-
viously.
26 For the detailed identification of each cylindrical
fragment, a map was constructed in an Excel spreadsheet to
permit the exact localization of each case. The TMA block
contained 265 thyroid cases (one core per case), correspond-
ing to fragments of normal thyroid tissue (NT, n = 18), NG
(n = 62), FA (n = 53), PTC (n = 41), FV-PTC (n = 31), FC (n
= 36), and M-TC (n = 24, including 17 fragments of PTC
metastases, 5 FV-PTC metastases, and 2 FC metastases).
A total of 120 histological 5-mm-thick sections were cut
from each TMA block. The slides were covered with a layer
of paraffin to prevent oxidation and stored in a freezer at
220˚C. Two slides from different levels of the TMA block
were used in this study.
Immunohistochemistry
Slides were left overnight in an oven at 56˚C, followed by
deparaffinization in xylene, graded alcohol, tap water and
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758distilled water. Heat-induced antigen retrieval was per-
formed using a domestic pressure cooker (Nigro, model
Eterna 41/2 L, Brazil) with a boiled 0.01 M sodium citrate
buffered solution (pH 6.0) for 4 min and cooled under
running water, as described previously.
27 Endogenous
peroxidase activity was quenched with 3% hydrogen
peroxide for 20 min. The antibody used was purchased
from Santa Cruz Biotechnology (NDRG1 N-19, catalog sc-
19464, Santa Cruz, CA, USA). The optimal dilution was
defined using a well-known positive sample that was tested
before it was used on TMA sections. The antibody was
diluted 1:1000 in 0.01 M phosphate-buffered saline (PBS),
pH 7.4, with 0.1% sodium azide (Sigma, catalog S8032, St.
Louis, MO, USA) and 1% bovine serum albumin (Sigma,
catalog A9647, USA) to reduce background staining and
incubated overnight at 4˚C in a moist chamber. The staining
procedure was performed using the labeled streptavidin-
biotin method (LSAB+ System-HRP, DakoCytomation,
catalog K0690, Carpinteria, CA, USA).
28 Slides were
incubated for 30 min at 37˚C with the Link, washed with
PBS and incubated for another 30 min at 37˚C with
streptavidin. The slides were developed with 60 mg 3,39-
diaminobenzidine tetrahydrochloride (Sigma, catalog
D5637, St Louis, MO, USA), 1% dimethyl sulfoxide
(Sigma, catalog D5879, St. Louis, MO, USA) and 0.06%
hydrogen peroxide in PBS for 5 min and counterstained
with Harris’s hematoxylin, dehydrated and mounted with
Entellan neu (Merck, catalog 1.07961, Damstadt, Germany).
A sample of FC was used as a positive control. A negative
control was performed by omitting the primary antibody.
Quantitative immunohistochemical evaluation
Cytoplasmic NDRG1 protein expression was analyzed
quantitatively using a computer image capture system
(Automated Cellular Imaging System - ACISH III, K0690;
Dako). The two slides were first scanned to capture and
digitalization the image. Next, parameters were established
regarding the staining intensity of NDRG1-immunostained
thyroid follicular cells and unstained stromal (fibroblasts
and endothelial cells) cells (‘‘blue area’’). Between two and
five circular areas per core were analyzed for each of the 265
cases in both slides. First, we calculated the integrated
optical density (IOD), which is related to the amount
(density) of the antigen.
29 A numerical value corresponding
to the IOD for each circular area was obtained by multi-
plying the staining intensity by the area of positive staining
(‘‘brown area’’). Then, the IOD was normalized to the tissue
area: the numerical IOD value was divided by the total
circular area (sum of the positively stained ‘‘brown area’’
and unstained ‘‘blue area’’).
30 For each core, the final
numerical value corresponded to the mean value of the
corrected IODs of the two to five circular areas analyzed.
Cores presenting more than 50% tissue loss were excluded
from the analysis. Finally, the mean of the final numerical
values obtained for the cores present in each of the two
slides was calculated for each case.
Statistical analysis
Box plots were constructed for the different thyroid
lesions using the results of the quantitative analysis of
NDRG1 immunohistochemical expression. These groups
were compared using the Kruskal-Wallis and Mann-
Whitney tests. For cases with a thyroid carcinoma diagnosis
(PTC, FV-PTC or FC), the association between the quanti-
tative immunohistochemical expression of NDRG1 and the
clinical-pathological variables (age, tumor size, TNM stage
and AMES risk classification) was determined using a
Student’s t-test. A P-value of less than 0.05 was considered
to be statistically significant. All statistical analyses were
performed using SPSS software, version 15.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
NDRG1 protein expression was observed in epithelial
(follicular) cells, with no staining in stromal or endothelial
cells. The positive cases showed moderate-to-strong cyto-
plasmic NDRG1 immunoreactivity (Figure 1). For each case
with a thyroid lesion and NT, the numerical values obtained
by the quantitative analysis of the immunohistochemical
expression of NDRG1 are reported as means and standard
deviations (Table 1). The quantitative expression of NDRG1
was higher in carcinomas compared to NTs and NGs, with
higher expression levels in PTC and M-TC (P , 0.001)
(Figure 2). When analyzed together, the quantitative
expression of NDRG1 was higher in the group of malignant
lesions (PTC, FV-PTC, FC, and M-TC) compared to the
group of benign thyroid lesions (NG and AF) (P = 0.043)
(Figure 3).
The association between the quantitative immunohisto-
chemical expression of NDRG1 and the clinical-pathological
variables was analyzed in cases of primary thyroid
carcinoma (PTC, FV-PTC and FC). In this group of tumors,
the quantitative expression of NDRG1 was significantly
higher in patients who were aged 45 years or older (P =
0.019), at an advanced TNM stage (stages III and IV) (P =
0.007), and in an AMES high-risk group (P = 0.012)
(Table 2).
DISCUSSION
To our knowledge, this is the first study to analyze the
immunohistochemical expression of the NDRG1 protein in a
large number of benign (NG and FA) and malignant (PTC,
FV-PTC, FC, and M-TC) thyroid lesions. We demonstrated
increased expression of NDRG1 in thyroid tumors com-
pared to NGs and NTs. Cangul also studied the immuno-
histochemical expression of NDRG1 in a variety of human
tumors (including breast, kidney, lung and prostate
carcinomas, and melanoma and glioblastoma multiforme)
and reported higher NDRG1 protein expression in tumors
compared to normal tissue.
18 In the colon, Wang et al.
observed increased NDRG1 expression in carcinomas
compared to adenomas and normal colon mucosa.
31 Reis
et al. analyzed 213,636 transcripts that were derived from
normal and tumor tissues of the oral cavity, larynx, pharynx
and thyroid using the open reading frame expressed
sequence tags (ORESTES) technique. Three (ZRF1, RAP140
and NDRG1) of the 250 potential markers selected in that
study were analyzed by quantitative RT-PCR in oral cavity
and laryngeal samples. The authors detected an increase in
the levels of NDRG1 mRNA in 50% of oral cavity tumors.
32
In contrast, Bandyopadhyay et al. observed lower NDRG1
immunohistochemical expression in breast carcinoma but
strong expression in normal mammary lobules.
33
The role of the NDRG1 protein in tumor progression and
metastasis formation is still controversial and is likely to be
tissue-specific. Several studies have shown that a decrease
in NDRG1 protein expression is associated with a more
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759advanced tumor stage and lower survival rates. In prostate
carcinomas, lower immunohistochemical expression of
NDRG1 was associated with a Gleason grade .7 and
poorly differentiated tumors. According to the authors, 70%
of localized prostate tumors expressed NDRG1, whereas
only 25% of metastatic tumors were positive for this
marker.
21 In breast cancer, 60% of patients with bone
metastases presented with reduced NDRG1 expression,
with survival being lower in patients whose tumors did not
express NDRG1.
33 In esophageal squamous cell carcinoma,
reduced NDRG1 expression was associated with more
invasive tumors and a more advanced TNM stage. In
addition, a lower survival rate was observed in patients
with low NDRG1 expression compared to those with high
expression.
34 A less differentiated histological grade, more
advanced pathological stage and lower overall survival
were correlated with reduced immunohistochemical expres-
sion of NDRG1 in pancreatic ductal adenocarcinoma.
35
We found that increased immunohistochemical expres-
sion of NDRG1 was correlated with a more advanced TNM
stage (stages III and IV) and an AMES high-risk category in
patients with thyroid carcinoma (PTC, FV-PTC, and FC). An
association between increased NDRG1 expression and more
aggressive tumors and poor prognosis has been reported in
other studies. Chua et al. observed that increased NDRG1
expression in hepatocellular carcinoma was associated with
a more advanced tumor stage (stages III and IV), larger
tumors and poorly differentiated tumors, according to the
Edmondson-Steiner histological classification. In their
study, patients whose tumors presented increased NDRG1
protein expression showed lower overall survival compared
Figure 1 - Immunohistochemical expression of NDRG1 in thyroid lesions. A. Nodular goiter; original magnification, 4006. B. Follicular
adenoma; original magnification, 4006. C. Classical papillary thyroid carcinoma; original magnification, 4006. D. Follicular variant of
papillary thyroid carcinoma; original magnification, 4006. E. Follicular carcinoma; original magnification, 4006. F. Metastatic classical
papillary thyroid carcinoma; original magnification, 2006.
Table 1 - Quantitative analysis of NDRG1
immunohistochemical expression in thyroid lesions.
Diagnosis N Mean Standard deviation
Normal thyroid 15 3.13 2.67
Nodular goiter 55 8.33 14.89
Follicular adenoma 51 17.30 27.11
Classical papillary thyroid carcinoma 39 29.22 25.82
Follicular variant of papillary
carcinoma
30 16.86 25.38
Follicular carcinoma 34 18.79 31.88
Thyroid carcinoma metastases
1 23 21.34 25.07
Eighteen cases were excluded from the analysis because of tissue loss
(normalthyroid,threecases;nodular goiter,sevencases;follicularadenoma,
two cases; classical papillary thyroid carcinoma, two cases; follicular variant
ofpapillary thyroid carcinoma,one case; follicularcarcinoma,two cases; and
papillary thyroid carcinoma metastases, one case).
1Includes 16 cases of classical papillary thyroid carcinoma metastasis, 5 of
follicular variant of papillary thyroid carcinoma, and 2 of follicular
carcinoma.
Kruskal-Wallis test, P , 0.001.
Figure 2 - NDRG1 expression in normal, benign and malignant
thyroid gland lesions. Box plot shows the data of the quantita-
tive immunohistochemical expression of NDRG1 for normal
thyroid (NT), nodular goiter (NG), follicular adenoma (FA),
classical papillary thyroid carcinoma (PTC), follicular variant of
papillary thyroid carcinoma (FV-PTC), follicular carcinoma (FC),
and metastases of thyroid carcinoma (M-TC) (P , 0.001, Kruskal-
Wallis test). The ‘‘o’’ and ‘‘*’’ symbols indicate outlier and
extreme outlier values, respectively.
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760to those with low NDRG1 levels.
22 In cervical adenocarci-
noma, increased immunohistochemical expression of
NDRG1 was correlated with a larger tumor diameter,
greater depth of stromal invasion, the presence of angio-
lymphatic invasion, a larger number of lymph node
metastases, poorly or moderately differentiated tumors
and poor prognosis, as demonstrated by lower progres-
sion-free and overall survival rates.
23
Some studies have suggested that NDRG1 is a metastasis
suppressor gene. Guan et al. observed lower NDRG1
expression in cell lines derived from colon cancer metas-
tases compared to cell lines derived from primary colon
cancer. Inducing NDRG1 expression in metastatic cell lines,
the authors observed that neoplastic cells expressed markers
related to cell differentiation of the colon epithelium, such as
CEA and E-cadherin.
20 In vivo studies have shown that cell
lines derived from colon and prostate cancers that were
transfected with NDRG1 and injected into mice produced a
smaller number of hepatic and pulmonary metastases,
respectively, than control lines.
20,21 However, in human
colorectal carcinoma samples, Wang et al. demonstrated
increased NDRG1 protein expression in primary tumors
with metastases to the lymph nodes compared to those
without metastases (non-metastatic carcinoma). The authors
concluded that higher NDRG1 expression was associated
with a higher probability of lymph node metastasis. Within
this context, according to the authors, NDRG1 could be a
gene that is involved in tumor progression and the
promotion of metastases of colorectal carcinoma.
31
CONCLUSIONS
The present study demonstrated an increase in the
immunohistochemical expression of NDRG1 in primary
and metastatic thyroid carcinomas compared to NT, NG,
and FA. We also observed an association between NDRG1
expression and a more advanced TNM stage and an AMES
high-risk category in patients with thyroid carcinoma (PTC,
FV-PTC, and FC). These findings suggest a role for NDRG1
in thyroid tumor progression. More detailed studies are
necessary to better define the role of NDRG1 in tumorigen-
esis and thyroid tumor progression, including the investiga-
tion of this protein in poorly differentiated or anaplastic
thyroid carcinomas.
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